

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT NO. 003300-920	APPLICATION NO. 10/088,639
<b>SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICANT Thomas BRODIN et al.	
		FILING DATE August 20, 2003	GROUP 1645

AUG 22 2003



U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

RECEIVED

AUG 25 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
LAI	Jerome DECOSSÉ et al., "Colorectal Cancer: Detection, Treatment, and Rehabilitation." CA Cancer J. Clin, Vol. 44, No. 1, January/February 1994, pp. 27-42. American Cancer Society, Atlanta, GA.
	G. RIETHMÜLLER et al., "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial." Journal of Clinical Oncology, Vol. 16, No. 5 (May), 1998, pp. 1788-1794. American Society of Clinical Oncology, Alexandria, VA.
	Joseph A. KUHN et al., "Monoclonal Antibodies and Colorectal Carcinoma: A Clinical Review of Diagnostic Applications." Cancer Investigation, 12(3), 1994, pp. 314-323. Marcel Dekker, Inc., New York, NY.
	Jesper TORDSSON et al., "Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections." Journal of Immunological Methods, 210 (1997), pp. 11-23. North Holland Publishing, Amsterdam, Holland.
	L. AUJAME et al., "High affinity human antibodies by phage display." Human Antibodies, 1997, Vol. 8, 4, pp. 155-168. IOS Press, Amsterdam, Holland.
	Robert K. CLARK, et al., "Immunohistochemical Analysis of Antiserum from Rhesus Monkeys Immunized with Human Colon Carcinoma." Cancer Research, 49, July 1, 1989, pp. 3656-3661. American Association for Cancer Research, Baltimore, MD.
	Alan P. LEWIS, et al. "Cloning and Sequence Analysis of κ and γ Cynomolgus Monkey Immunoglobulin cDNAs," Developmental and Comparative Immunology, Vol. 17, 1993, pp. 549-560. Pergamon Press Ltd., Oxford, UK.
	Thomas N. BRODIN et al., "Man-made superantigens: Tumor-selective agents for T-cell-based therapy." Advanced Drug Delivery Reviews 31 (1998) pp. 131-142. Elsevier Science B.V., Amsterdam, Holland.
↓	Mikael DOHLSTEN et al., "Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy." Proc. Natl. Acad. Sci USA, Vol. 91, September 1994, Immunology, pp. 8945-8949. National Academy of Sciences, Washington, D.C.
LAI	Changnian LIU, et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids." Proc. Natl. Acad. Sci USA, Vol. 93, August 1996, Medical Sciences, pp. 8618-8623. National Academy of Sciences, Washington, D.C.

Examiner Signature		Date Considered	9/30/02
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10 / 088639  
JC13 Rec'd PCT/PTO 20 MAR 2002  
SHEET 1 OF 1

Substitute for form 1449A/PTO	ATTORNEY'S DKT N 003300-920	APPLICATION NO. unassigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	APPLICANT THOMAS BRODIN et al.	
	FILING DATE March 20, 2002	GROUP unassigned

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.